| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01110291 | CYP3A Phenotyping|CYP3A5 and MDR1 Genotyping|Docetaxel Toxicity|Associations Between Genetic Data and Docetaxel Toxicity | Drug: docetaxel + CEF | University of Turku|Sanofi|Turku University Hospital|Vaasa Central Hospital, Vaasa, Finland|medbase Oy Ltd | | 2003-04-01 | 2010-04-26 |
| NCT01019941 | Advanced Solid Cancers | Drug: CKD-810, Taxotere inj.|Drug: CKD-810, Taxotere inj. | Chong Kun Dang Pharmaceutical | Phase 1 | 2009-08-01 | 2010-12-15 |
| NCT00675545 | Hormone-Refractory Prostate Cancer | Drug: Docetaxel, Carboplatin | National University Hospital, Singapore | Phase 2 | 2007-05-01 | 2012-03-30 |
| NCT00795171 | Hormone Refractory Prostate Cancer | Drug: Docetaxel * Sunitinib|Drug: Docetaxel|Drug: Docetaxel | Medical University of Vienna | Phase 2 | 2008-11-01 | 2010-08-17 |
| NCT00606814 | Solid Tumors | Drug: IPI-504, docetaxel | Infinity Pharmaceuticals, Inc. | Phase 1 | 2007-12-01 | 2012-03-02 |
| NCT00630110 | Cancer | Drug: docetaxel|Drug: NPI-2358 + docetaxel | Nereus Pharmaceuticals, Inc. | Phase 1|Phase 2 | 2008-02-01 | 2011-08-15 |
| NCT00714376 | Prostate Cancer | Drug: Docetaxel | Centre Hospitalier Universitaire de Qubec, CHU de Qubec | Phase 2 | 2008-05-01 | 2012-10-30 |
| NCT01949519 | Adenocarcinoma of the Prostate | Drug: Lycopene and Docetaxel | Medical University of South Carolina|National Cancer Institute (NCI) | Phase 1 | 2013-11-01 | 2016-10-18 |
| NCT01254513 | Prostate Cancer | Drug: Docetaxel every 3 weeks + Prednisone|Drug: Docetaxel weekly+ Prednisone | UNICANCER | Phase 2 | 2010-11-01 | 2013-01-29 |
| NCT00703378 | Solid Tumors | Drug: Docetaxel (Taxotere) | National University Hospital, Singapore | Phase 1|Phase 2 | 2006-05-01 | 2012-03-27 |
| NCT01837667 | Tumors|Neoplasms|Cancer | Drug: LB-100 for Injection|Drug: Docetaxel | Lixte Biotechnology Holdings, Inc. | Phase 1 | 2013-02-01 | 2017-01-23 |
| NCT00248703 | Breast Cancer | Drug: Docetaxel | Oslo University Hospital|University of Tromso|Helse Stavanger HF|Sorlandet Hospital HF|Sykehuset Innlandet HF|Ullevaal University Hospital|Sykehuset i Vestfold HF|Sykehuset Ostfold|Alesund Hospital | Phase 2 | 2003-10-01 | 2012-11-20 |
| NCT01256359 | Melanoma | Drug: Docetaxel and AZD6244|Drug: Docetaxel and placebo | University of Oxford | Phase 2 | 2010-10-01 | 2016-06-21 |
| NCT02274610 | Solid Tumor | Drug: Docetaxel-PNP|Drug: Taxotere | Samyang Biopharmaceuticals Corporation | Phase 1 | 2014-11-01 | 2014-10-23 |
| NCT00169000 | Metastatic Breast Cancer | Drug: Capecitabine|Drug: Docetaxel | Dartmouth-Hitchcock Medical Center|Hoffmann-La Roche | Phase 1 | 2003-01-01 | 2009-08-04 |
| NCT00030407 | Lung Cancer | Drug: Celecoxib|Drug: Docetaxel | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) | Phase 2 | 2001-10-01 | 2013-04-25 |
| NCT00582634 | Non Small Cell Lung Cancer | Drug: docetaxel and cisplatin | University of Wisconsin, Madison | Phase 2 | 2004-09-01 | 2015-09-30 |
| NCT00080665 | Breast Cancer | Drug: docetaxel|Drug: imatinib mesylate | Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) | Phase 1 | 2003-12-01 | 2016-11-04 |
| NCT01336582 | Solid Tumor | Drug: taxotere | Samyang Biopharmaceuticals Corporation | Phase 1 | 2009-08-01 | 2012-12-19 |
| NCT01693432 | Esophageal Neoplasms | Drug: DS (docetaxel+S-1) | Hallym University Medical Center|Jeil Pharmaceutical Co., Ltd. | Phase 2 | 2011-11-01 | 2016-09-27 |
